Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 3
1989 4
1990 6
1991 5
1992 6
1993 6
1994 6
1995 8
1996 3
1997 7
1998 11
1999 8
2000 14
2001 17
2002 26
2003 23
2004 21
2005 10
2006 13
2007 5
2008 10
2009 4
2010 5
2011 6
2012 9
2013 7
2014 2
2015 2
2016 1
2017 2
2018 5
2019 11
2020 7
Text availability
Article attribute
Article type
Publication date

Similar Articles for PMID: 12660333

260 results
Results by year
Filters applied: . Clear all
Page 1
Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy.
Jacobsen P, Andersen S, Jensen BR, Parving HH. Jacobsen P, et al. J Am Soc Nephrol. 2003 Apr;14(4):992-9. doi: 10.1097/01.asn.0000054495.96193.bf. J Am Soc Nephrol. 2003. PMID: 12660333 Free article. Clinical Trial.
Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy.
Jacobsen P, Andersen S, Rossing K, Jensen BR, Parving HH. Jacobsen P, et al. Kidney Int. 2003 May;63(5):1874-80. doi: 10.1046/j.1523-1755.2003.00940.x. Kidney Int. 2003. PMID: 12675866 Free article. Clinical Trial.
Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy.
Jacobsen P, Andersen S, Rossing K, Hansen BV, Parving HH. Jacobsen P, et al. Nephrol Dial Transplant. 2002 Jun;17(6):1019-24. doi: 10.1093/ndt/17.6.1019. Nephrol Dial Transplant. 2002. PMID: 12032191 Clinical Trial.
Additive hypotensive effect of angiotensin-converting enzyme inhibition and angiotensin-receptor antagonism in essential hypertension.
Stergiou GS, Skeva II, Baibas NM, Roussias LG, Kalkana CB, Achimastos AD, Mountokalakis TD. Stergiou GS, et al. J Cardiovasc Pharmacol. 2000 Jun;35(6):937-41. doi: 10.1097/00005344-200006000-00017. J Cardiovasc Pharmacol. 2000. PMID: 10836730 Clinical Trial.
Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial.
Rossing K, Jacobsen P, Pietraszek L, Parving HH. Rossing K, et al. Diabetes Care. 2003 Aug;26(8):2268-74. doi: 10.2337/diacare.26.8.2268. Diabetes Care. 2003. PMID: 12882847 Clinical Trial.
Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease.
Ruilope LM, Aldigier JC, Ponticelli C, Oddou-Stock P, Botteri F, Mann JF. Ruilope LM, et al. J Hypertens. 2000 Jan;18(1):89-95. J Hypertens. 2000. PMID: 10678548 Clinical Trial.
Effects of add-on fluvastatin therapy in patients with chronic proteinuric nephropathy on dual renin-angiotensin system blockade: the ESPLANADE trial.
Ruggenenti P, Perna A, Tonelli M, Loriga G, Motterlini N, Rubis N, Ledda F, Rota S Jr, Satta A, Granata A, Battaglia G, Cambareri F, David S, Gaspari F, Stucchi N, Carminati S, Ene-Iordache B, Cravedi P, Remuzzi G; ESPLANADE Study Group. Ruggenenti P, et al. Clin J Am Soc Nephrol. 2010 Nov;5(11):1928-38. doi: 10.2215/CJN.03380410. Epub 2010 Jul 29. Clin J Am Soc Nephrol. 2010. PMID: 20671225 Free PMC article. Clinical Trial.
Comparison of the efficacy and safety profiles of two fixed-dose combinations of antihypertensive agents, amlodipine/benazepril versus valsartan/hydrochlorothiazide, in patients with type 2 diabetes mellitus and hypertension: a 16-week, multicenter, randomized, double-blind, noninferiority study.
Lee IT, Hung YJ, Chen JF, Wang CY, Lee WJ, Sheu WH. Lee IT, et al. Clin Ther. 2012 Aug;34(8):1735-50. doi: 10.1016/j.clinthera.2012.06.014. Epub 2012 Jul 10. Clin Ther. 2012. PMID: 22784975 Clinical Trial.
260 results
Jump to page
Feedback